Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$25.92 USD
+1.46 (5.97%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $25.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Celldex Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CLDX 25.92 +1.46(5.97%)
Will CLDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Other News for CLDX
Is CLDX setting up for a drop? Shooting Star Candlestick shows up after sliding 0.49%
Celldex (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in CSU
Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
Celldex's barzo shows strong efficacy in CSU patients, says H.C. Wainwright